Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada

Vaccine

Volumn 32, Issue 28, 2014, Pages 3480-3487

  Rouleau, Isabelle ^a   De Serres, Gaston ^a,b   Skowronski, Danuta M ^c   Drolet, Jean Philippe ^a   Lemire, Chantal ^d   Toth, Eveline ^e   Landry, Monique ^e  

^a LAVAL UNIVERSITY   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^e Ministère de la Santé et des Services Sociaux du Québec   (Canada)

Author keywords

Adverse effects; Anaphylaxis; Hypersensitivity; Influenza vaccine; Pandemic influenza; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; ADRENALIN; ALCOHOL; ANALGESIC AGENT; INFLUENZA VACCINE; OPIATE; SULFONAMIDE; THIOMERSAL; IMMUNOLOGICAL ADJUVANT;

ABDOMINAL PAIN; ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; ADULT; AGED; ALCOHOL CONSUMPTION; ALLERGY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CANADA; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; COUGHING; CYANOSIS; DEMOGRAPHY; DRUG ERUPTION; DRUG USE; DYSPNEA; EYE REDNESS; FEMALE; FOOD ALLERGY; HISTORY; HOARSENESS; HUMAN; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; NAUSEA; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PRURITUS; RISK FACTOR; RISK REDUCTION; TACHYPNEA; TELEPHONE INTERVIEW; UNCONSCIOUSNESS; VOMITING; WHEEZING; CASE CONTROL STUDY; CHEMICALLY INDUCED; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; MIDDLE AGED; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANAPHYLAXIS; CASE-CONTROL STUDIES; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; QUEBEC; RISK FACTORS; YOUNG ADULT;

EID: 84901469196     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.059     Document Type: Article

References (34)

1. Auger D., Bourdages J., Dubuque J., Hudon N., Markowski F., Toth E. Bilan de la Direction générale de la santé publlique de la vaccination contre la grippe pandémique A(H1N1) du 22 octobre au 18 décembre 2009 2011, Ministère de la Santé et des Services sociaux du Québec. Gouvernement du Québec.
2. Rouleau I., De Serres G., Drolet J.P., Skowronski D.M., Ouakki M., Toth E., et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1 pdm09) vaccine. Vaccine 2013, 31:5989-5996.
3. Rouleau I., De Serres G., Drolet J.P., Banerjee D., Lemire C., Moore A., et al. Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE. J Allergy Clin Immunol 2012, 130:1423-1426.
4. Freitas D.R., Moura E., Araujo G., Cardoso A., Scheidt P., Ferraz E., et al. Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. Vaccine 2013, 31:950-954.
5. Hwang S.M., Choe K.W., Cho S.H., Yoon S.J., Park D.E., Kang J.S., et al. The adverse events of influenza A (H1N1) vaccination and its risk factors in healthcare personnel in 18 military healthcare units in Korea. Jpn J Infect Dis 2011, 64:183-189.
6. Simons F.E., Ardusso L.R., Bilo M.B., Dimov V., Ebisawa M., El-Gamal Y.M., et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012, 12:389-399.
7. Simons F.E., Ardusso L.R., Bilo M.B., El-Gamal Y.M., Ledford D.K., Ring J., et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 2011, 4:13-37.
8. Simons F.E., Ardusso L.R., Dimov V., Ebisawa M., El-Gamal Y.M., Lockey R.F., et al. World allergy organization anaphylaxis guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 2013, 162:193-204.
9. Lee S., Hess E.P., Nestler D.M., Bellamkonda Athmaram V.R., Bellolio M.F., Decker W.W., et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol 2013, 131:1103-1108.
10. Gouvernement du Québec Loi sur la santé publique (L.R.Q., chapitre S-2.2, mis à jour le 1er mars 2005) 2001.
11. National Advisory Committee on Immunization Canadian Immunization Guide 2006, Public Health Agency of Canada, Ottawa. 7th edition.
12. Lacroix K., Rouleau I., Dupré N., Benoît M., Ouakki M., Skowronski D., et al. Anesthesia/paresthesia following immunization with an adjuvanted monovalent pandemic influenza vaccine: results of an epidemiological investigation in Quebec, Canada. American Academy of Neurology 2011 Annual Meeting 2011.
13. WHO Collaborating Centre for Drug Statistics Methodology Guidelines for ATC classification and DDD assignment 2013 2012, WHO Collaborating Centre for Drug Statistics Methodology, Oslo.
14. Rüggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5675-5684.
15. De Serres G., Grenier J.-L., Toth E., Ménard S., Roussel R., Tremblay M., et al. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine 2003, 21:2354-2361.
16. Kelso J.M. Adverse reactions to vaccines for infectious disease. Middleton's allergy: principles & practice 2009, Mosby/Elsevier, Philadelphia, PA. 7th ed. N.F. Adkinson, E. Middleton (Eds.).
17. Thompson D. Ranking predictors in logistic regression. MWSUG 2009, Proceedings, Midwest SAS Users Group, Inc., Paper D10-2009 2009.
18. Robb H., Fausone C.A., Rudy D.R., McArthur S. Side effects from influenza vaccination: differences between returned and random surveys. Mil Med 1996, 161:29-32.
19. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26:3551-3555.
20. Engler R.J., Nelson M.R., Klote M.M., VanRaden M.J., Huang C.Y., Cox N.J., et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008, 168:2405-2414.
21. Edwards K.M., Burns V.E., Reynolds T., Carroll D., Drayson M., Ring C. Acute stress exposure prior to influenza vaccination enhances antibody response in women. Brain Behav Immun 2006, 20:159-168.
22. Edwards K.M., Burns V.E., Allen L.M., McPhee J.S., Bosch J.A., Carroll D., et al. Eccentric exercise as an adjuvant to influenza vaccination in humans. Brain Behav Immun 2007, 21:209-217.
23. Hui S.L., Chu L.W., Peiris J.S., Chan K.H., Chu D., Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine 2006, 24:5371-5380.
24. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007, 25:7656-7663.
25. Goronzy J.J., Fulbright J.W., Crowson C.S., Poland G.A., O'Fallon W.M., Weyand C.M. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001, 75:12182-12187.
26. Cook I.F., Barr I., Hartel G., Pond D., Hampson A.W. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2006, 24:2395-2402.
27. Wolbing F., Fischer J., Koberle M., Kaesler S., Biedermann T. About the role and underlying mechanisms of cofactors in anaphylaxis. Allergy 2013, 68:1085-1092.
28. Rosenberg M., Tram C., Kuper A., Daneman N. Rash associated with pandemic (H1N1) influenza. Can Med Assoc J 2010, 182:E146.
29. Fretzayas A., Moustaki M., Kotzia D., Nicolaidou P. Rash an uncommon but existing feature of H1N1 influenza among children. Influenza Other Respir Viruses 2011, 5:223-224.
30. Romeo J., Warnberg J., Nova E., Diaz L.E., Gomez-Martinez S., Marcos A. Moderate alcohol consumption and the immune system: a review. Br J Nutr 2007, 98(Suppl. 1):S111-S115.
31. Kovacs E.J., Messingham K.A. Influence of alcohol and gender on immune response. Alcohol Res Health: J Natl Inst Alcohol Abuse Alcohol 2002, 26:257-263.
32. Cates J.R., Shafer A., Diehl S.J., Deal A.M. Evaluating a county-sponsored social marketing campaign to increase mothers' initiation of HPV vaccine for their pre-teen daughters in a primarily rural area. Soc Mar Q 2011, 17:4-26.
33. Davis C.G., Thake J., Vilhena N. Social desirability biases in self-reported alcohol consumption and harms. Addict Behav 2010, 35:302-311.
34. Éduc Alcool Les Québécois et l'alcool 2012 2012, 70. Éduc Alcool, Québec.